
Hologic (HOLX) Stock Forecast & Price Target
Hologic (HOLX) Analyst Ratings
Bulls say
Hologic is poised for strong financial performance, with expectations of 5-7% organic revenue growth driven by robust procedure volume growth and new product launches across its Diagnostics, Breast Health, and GYN Surgical segments. The company’s bull case scenario projects revenue growth accelerating to 7-9%, supported by improved operating margins and a robust balance sheet, which suggests a solid operational foundation for future expansion. Additionally, Hologic's strategies for margin enhancement, including potential tuck-in acquisitions and operational efficiencies, align well with projections of 8-12% earnings growth, positioning the company favorably for long-term success.
Bears say
Hologic's stock outlook remains negative due to anticipated revenue growth slowing to the low single digits (1-4%), primarily driven by weaknesses in the Diagnostics and Breast Health segments, which could lead to operating margins worse than expected and below-consensus earnings. The company's performance has been disappointing, with share prices down approximately 3.1% year-to-date and only modest increases of 9.4% and 4.4% over the last three and five years, respectively, suggesting persistent growth challenges. Risks such as a reduced demand for products amid a weakening global economy, integration difficulties from recent acquisitions, and increasing competition in key segments further exacerbate the company's growth and profitability outlook.
This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.
Hologic (HOLX) Analyst Forecast & Price Prediction
Start investing in Hologic (HOLX)
Order type
Buy in
Order amount
Est. shares
0 shares